NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Hold” by Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has received a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $13.8571.

A number of equities analysts have recently issued reports on the company. Weiss Ratings downgraded NeoGenomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. TD Cowen raised their price target on NeoGenomics from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $12.00 to $25.00 in a research note on Wednesday, April 29th. William Blair restated a “market perform” rating on shares of NeoGenomics in a research note on Monday, March 16th. Finally, Zacks Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th.

NeoGenomics Stock Down 3.1%

NeoGenomics stock opened at $10.12 on Wednesday. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -13.14 and a beta of 1.82. The stock has a fifty day simple moving average of $8.48 and a two-hundred day simple moving average of $10.28. NeoGenomics has a 12 month low of $4.72 and a 12 month high of $13.74. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. The business had revenue of $186.67 million during the quarter, compared to analyst estimates of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The company’s revenue was up 11.3% on a year-over-year basis. Equities analysts predict that NeoGenomics will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

A number of institutional investors and hedge funds have recently modified their holdings of the company. First Horizon Corp boosted its stake in shares of NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after buying an additional 865 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its stake in shares of NeoGenomics by 42.5% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after buying an additional 997 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of NeoGenomics by 1.7% in the 4th quarter. State of Alaska Department of Revenue now owns 73,044 shares of the medical research company’s stock worth $858,000 after buying an additional 1,215 shares during the last quarter. Choreo LLC lifted its position in NeoGenomics by 2.2% during the fourth quarter. Choreo LLC now owns 61,462 shares of the medical research company’s stock valued at $752,000 after purchasing an additional 1,313 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in NeoGenomics by 68.2% during the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,460 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.